Enveda, a clinical-stage biotechnology company that uses AI to discover medicines from life's chemistry, announced the close of a $311 million Series E financing led by Catalio Capital Management, with new investment from Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital (a Citadel company), accounts advised by T. Rowe Price Investment Management, Digitalis Ventures, a notable Sovereign Wealth Fund, and Alderline Group alongside existing investors Baillie Gifford, Premji Invest, FPV Ventures, True Ventures, Kinnevik, Dimension, Lifeforce Capital, and Lux Capital. In connection with the financing, George Petrocheilos, Co-Founder and Managing Partner of Catalio Capital Management, has joined Enveda's Board of Directors.

The round follows two positive early clinical readouts in 2026, in atopic dermatitis and in metabolic health, for medicines Enveda discovered with PRISM, and brings the company's total capital raised since inception to more than $845 million, enabling the company to advance multiple programs through the clinic and execute on the next stage of its pipeline and platform growth.